Josh Disbrow holds the positions of Chief Executive Officer and Board Director at Aytu BioPharma, a company he co-founded in 2015. Under his visionary guidance, Aytu BioPharma achieved a remarkable milestone by securing a NASDAQ listing in 2017 and, within just seven years, surpassing the $100 million mark in annual revenues. Alongside steering the company's exponential growth, Josh has adeptly overseen the completion of four company acquisitions in less than four years, further solidifying his impactful leadership. Also, Josh is a Director at Zynex, Inc., a publicly-listed medical device enterprise focusing on electrotherapy and pain management. His role extends to proudly chairing the Nominating and Governance Committee, underscoring his unwavering commitment to upholding strong corporate governance principles. Commencing as a sales representative at Glaxo Wellcome (now GlaxoSmithKline plc), his trajectory led him to pivotal commercial and leadership roles at Cyberonics, LipoScience, Arbor Pharmaceuticals, and Ampio Pharmaceuticals.
Their philanthropic endeavors encompass Colorado-based Invest-in-Kids and their annual Jane-A-Thon fundraiser, significantly benefiting children and young families across the state. They also demonstrate consistent support for local churches and multiple charitable organizations. Reflecting his commitment to service, Joshua actively participated in a recent mission trip to Puerto Penasco, Mexico, where he contributed to building a home for a needy family. This commitment to service extends within Aytu BioPharma, where employees are granted a dedicated Volunteer Day, aligning with his leadership-by-example philosophy. Music resonates deeply with him, with a passion for guitar playing that traces back
